Steven I Sherman
Overview
Explore the profile of Steven I Sherman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
15532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marczyk V, Fazeli S, Dadu R, Busaidy N, Iyer P, Hu M, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400321.
PMID: 39983078
Purpose: Neurotrophic tropomyosin receptor kinase () fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their...
2.
Dudzinski S, Cabanillas M, Hamidi S, Marczyk V, Busaidy N, Dadu R, et al.
J Natl Compr Canc Netw
. 2024 Dec;
23(1.
PMID: 39662038
Background: Definitive radiotherapy (dRT) has been shown to be an effective option for patients with oligometastatic and oligoprogressive cancers; however, this approach has not been well-studied in metastatic thyroid cancer....
3.
Hamidi S, Yedururi S, Hu M, Busaidy N, Sherman S, Jimenez C, et al.
Thyroid
. 2024 Dec;
35(1):6-17.
PMID: 39630530
Two selective RET inhibitors (RETis) are effective in treating ()-altered medullary thyroid carcinoma (MTC), but clinical trials did not distinguish responses between hereditary MTC (hMTC) and sporadic MTC (sMTC) cases....
4.
Li S, Zheng G, Xu L, Goswami M, Zafereo M, Sherman S, et al.
JAMA Otolaryngol Head Neck Surg
. 2024 Nov;
151(2):113-120.
PMID: 39602114
Importance: Genome-wide association studies have identified germline variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to construct a polygenic score (PGS). It is important...
5.
Wu W, Luke B, Wu X, Lee J, Yi Y, Okpechi S, et al.
JNCI Cancer Spectr
. 2024 Sep;
8(5).
PMID: 39270065
Background: The consequence of diabetes on lung cancer overall survival (OS) is debated. This retrospective study used 2 large lung cancer databases to assess comprehensively diabetes effects on lung cancer...
6.
Shirali A, Hu M, Chiang Y, Graham P, Fisher S, Sosa J, et al.
J Endocr Soc
. 2024 Apr;
8(6):bvae048.
PMID: 38660141
Context: Next-generation sequencing (NGS) analysis of sporadic medullary thyroid carcinoma (sMTC) has led to increased detection of somatic mutations, including M918T, which has been considered a negative prognostic indicator. Objective:...
7.
Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman S, Jarzab B, et al.
Thyroid
. 2023 Dec;
34(3):347-359.
PMID: 38062732
Lenvatinib and sorafenib are standard of care first-line treatments for advanced, radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC). However, most patients eventually become treatment-resistant and require additional therapies. The phase 3...
8.
Murray S, Subbiah V, Sherman S, Peloquin S, Sireci A, Grohe C, et al.
Thyroid Res
. 2023 Aug;
16(1):22.
PMID: 37574538
Background: The discovery of driver oncogenes for thyroid carcinomas and the identification of genomically targeted therapies to inhibit those oncogenes have altered the treatment algorithm in thyroid cancer (TC), while...
9.
Lazure P, Sireci A, Subbiah V, Murray S, Grohe C, Sherman S, et al.
BMC Med Educ
. 2023 Jun;
23(1):410.
PMID: 37277734
Background: The introduction of new targeted therapies for RET-altered lung and thyroid cancers (LC/TC) has impacted pathologists' practice by making genomic testing more relevant. Variations in health systems and treatment...
10.
Brose M, Robinson B, Sherman S, Jarzab B, Lin C, Vaisman F, et al.
Cancer
. 2022 Oct;
128(24):4203-4212.
PMID: 36259380
Background: At an interim analysis (median follow-up, 6.2 months; n = 187), the phase 3 COSMIC-311 trial met the primary end point of progression-free survival (PFS): cabozantinib improved PFS versus...